17Sep/20

Design ADC with Creative Biolabs-Episode I

September 17, 2020ReviewADC design, DAR, tumor targetbioadc

As we all known, antibody-drug conjugate (ADC) is a drug obtained by chemical conjuagtion of antibody, linker and cytotoxin. Compared with simple monoclonal antibodies, ADC has better targeting and more efficient killingRead More…

17Sep/20

Blockbuster Deal for ADC: Merck Sharp & Dohme and Seattle Genetics Reach a $4.5 Billion Partnership

September 17, 2020NewsADC, HER2, ladiratuzumab vedotin, LIV-1, Trop-2bioadc

On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…

17Sep/20

Big Deal: Gilead Acquired Immunomedics for Nearly $20 Billion to Get Hot ADC Drugs

September 17, 2020NewsADC, breast cancer, Trop-2, trophoblast surface antigen 2bioadc

On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…

20Aug/20

Medical Missile-ADC Drug-Will Take-Off

August 20, 2020News, UncategorizedADC, ADC development, ADC linkers, ADC toxinsbioadc

Recently, AstraZeneca reached a global development and commercialization agreement of up to US $6 billion with the Daiichi Sankyo Company Limited for the development and commercialization of the antibody-drug conjugate (ADC). ThisRead More…

12Jun/19

A Noval ADC for DLBCL Get Accelerated Approval

June 12, 2019NewsADC, chemoimmunotherapy, DLBCLbioadc

Recently, the United States Food and Drug Administration announced the accelerated approval of the antibody-conjugate drug (ADC) Polivy (polatuzumab vedotin-piiq) for the treatment of refractory adult patients with diffuse large B-cell lymphomaRead More…

07May/19

New Clinical Development Model of Kadcyla approved for the treatment of early mammary cancer

May 7, 2019NewsDM1, Early mammary cancer, HER2, Kadcylabioadc

The United States FDA approved the extended indication of its antibody coupling drug Kadcyla (ado-trastuzumab emtansine) as a postoperative adjunctive therapy for early mammary cancer patients with positive HER2 and still residualRead More…

03Apr/19

BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year

April 3, 2019Antibody-drug Conjugates ResearchADC, Auristatin F, BCMA, GSK2857916bioadc

British pharmaceutical company GlaxoSmithKline (GSK) recently announced the clinical study DREAMM -1 (NCT02064387) further positive data of experimental anti-B cell mature antigen (BCMA) antibody drug conjugate (ADC) GSK2857916 in the treatment ofRead More…

08Mar/19

ADC-Polatuzumab Vedotin targeting CD79b has been prioritized by FDA in the United States

March 8, 2019Antibody-drug Conjugates Research, NewsADC, CD79b, fda, Polatuzumab Vedotinbioadc

Roche recently announced that the Food and Drug Administration (FDA) has accepted the biological product licensing application (BLA) of the antibody drug conjugate (ADC) Polatuzumab Vedotin and granted priority review qualifications forRead More…

12Feb/19

Immunomedics triple negative breast cancer ADC drug rejected by FDA in the United States

February 12, 2019Antibody-drug Conjugates Research, NewsADC, SN-38, TNBC, triple negative breast cancerbioadc

Immunomedics is a clinical biopharmaceutical company specializing in the development of monoclonal antibody-based therapies for the targeted treatment of cancer and other serious diseases. Recently, the company’s antibody-drug conjugate (ADC) sacituzumab govitecanRead More…

11Jan/19

ADC drug Based on Photoimmunotherapy Secured $284 Million in Series C Financing

January 11, 2019NewsADC, EGFR, Photoimmunotherapybioadc

Recently, Rakuten Aspyrian, a clinical stage biotechnology company, announced a total of $284 million in Series C funding round with its antibody-drug conjugates based on photoimmunotherapy, including $134 million jointly funded byRead More…